ab-205

Cell therapyexperimental

Clinical trial activity

2 trials · 2 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
1
Phase 3
1
Phase 4
0

Earliest trial started May 7, 2019 (NCT03925935)

Timeline

2010s

  1. Jan 1, 2019

    Earliest Phase 1 Sponsor(trial)

2020s

  1. Jan 1, 2022

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

  • Unspecified targetTissue restoration

    tissue restoration

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05181540Phase 3Feb 21, 2022Angiocrine Bioscience, California Institute for Regenerative Medicine (CIRM)
NCT03925935Phase 1May 7, 2019Angiocrine Bioscience, California Institute for Regenerative Medicine (CIRM)
Showing 2 of 2 trials
Page 1 / 1

Organizations

Research & Development (2)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Angiocrine BioscienceFor profit2222019
California Institute for Regenerative Medicine (CIRM)Academic/Hospital2022019
2 organizations
Page 1 / 1